Invictus Nutraceuticals, Inc. (Florida, USA), a wholly owned subsidiary of VGI Health Technology Limited (NSX:VTL), is pleased to announce that it has partnered with Informed Sport to certify its NE1-Elite(R) product.
Anatara Lifesciences (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in animals and humans, is pleased to announce the successful completion of a challenge study in weaner piglets with its recently developed bromelain-based formulation (BONIFF).
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce a research collaboration with Professor Christopher Little and the Raymond Purves Bone and Joint Research Laboratory at the Kolling Institute at Royal North Shore Hospital, Australia.
Anatara Lifesciences Limited (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in animals and humans, is pleased to provide this activities report for the quarter ending 30 June 2021 (Q4 FY21), along with the Company's Appendix 4C cash flow report.
Anatara Lifesciences (ASX:ANR), a developer of evidence-based solutions for gastrointestinal diseases in humans and animals, is pleased to announce the transition of Dr David Brookes from Non-Executive Director to Chairman.
VGI Health Technology Limited (NSX:VTL) recently signed a manufacturing and supply agreement with a US manufacturer, Altipure LLC, for finished nutraceutical products for sale and clinical study drugs for our clinical studies.
iQX Limited (NSX:IQX), on behalf of Life Science Biosensor Diagnostics Pty Ltd (LSBD), in which IQX holds 19% equity position, that LSBD's subsidiary GBS today announced it has been awarded a AUD $6.3 million, Australian Federal Government scientific grant.
